

Certificate of Analysis

www.tocris.com

Product Name: CP 471474

Catalog No.: 3780

Batch No.: 1

CAS Number: 210755-45-6

IUPAC Name: 2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydroxy-2-methylpropanamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₆H₁₆FN₂O₅S


Batch Molecular Weight: 368.38

Physical Appearance: Off-white solid

Solubility: DMSO to 100 mM

Storage: Store at -20°C

Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 97.5% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	52.17	4.65	7.6
Found	52.17	4.63	7.55

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: CP 471474

Catalog No.: 3780

Batch No.: 1

CAS Number: 210755-45-6

IUPAC Name: 2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydroxy-2-methylpropanamide

Description:

Broad spectrum MMP inhibitor (IC₅₀ values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.

Physical and Chemical Properties:


Batch Molecular Formula: C₁₆H₁₆FN₂O₅S

Batch Molecular Weight: 368.38

Physical Appearance: Off-white solid

Minimum Purity: >97%

Batch Molecular Structure:



Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Rohde et al (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. *Circulation* **99** 3063. PMID: 10368126.

Lindsey et al (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. *Circulation* **105** 753. PMID: 11839633.

Fang et al (2007) Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. *J.Mol.Cell.Cardiol.* **43** 535. PMID: 17689559.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel: +1 612 379 2956